Moreover, inhibition of CHK1 or PARP has been found to increase the levels of tumor-infiltrating T lymphocytes and synergize with anti-PD-L1 therapy, suggesting that DDR inhibitor treatment could enhance the efficacy of ICIs in SCLC patients88. This evidence concerns the gene CHEK1 and small cell lung carcinoma.